Approximately 50% of cutaneous melanoma patients are mutant in BRAF gene, 15–20% of patients are positive for NRAS damaging mutations both leading to a constitutively enhanced MAPK pathway activity [44]. The gene discussed is BRAF; the disease is cutaneous melanoma.